Rahko’s Co-founder and former VP of AI at Odyssey Therapeutics will lead the technical growth of LabGenius’ ML-driven drug discovery platform LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use ...

At an old biscuit factory in South London, giant mixers and industrial ovens have been replaced by robotic arms, incubators, and DNA sequencing machines. James Field and his company LabGenius aren’t ...

LONDON--(BUSINESS WIRE)--LabGenius, a pioneer in the use of machine learning (ML) for protein engineering, today announced the signing of a multi-year research collaboration with Ablynx, a Sanofi ...

LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) Annual 2023 Meeting ...

With over 30 years of industry experience, the former Global Head of Licensing at Servier Group will spearhead LabGenius’ business development, commercial strategy, and operational delivery.

LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding. The round is led by Lux Capital and Obvious Ventures, with ...

For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™, was used to discover and concomitantly optimise a TCE with improved killing ...

LONDON, December 04, 2025--(BUSINESS WIRE)--LabGenius Therapeutics ("LabGenius"), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential ...

Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVA TM, to the optimization of therapeutic NANOBODY ® proteins LONDON–(BUSINESS WIRE)–July 15, 2021– ...